Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proteasome subunit beta type-9 (PSMB9), also known as LMP2 or proteasome beta-1i subunit, is a catalytic subunit of the immunoproteasome, a specialized form of the 20S proteasome core. It is constitutively expressed in hematopoietic cells and can be induced in non-hematopoietic cells by inflammatory cytokines, particularly interferon-gamma (IFN-gamma). PSMB9 replaces the constitutive beta-1c subunit (PSMB6) to alter the cleavage specificity of the proteasome, favoring the generation of hydrophobic and basic peptides that are optimal for loading onto major histocompatibility complex (MHC) class I molecules. This process is essential for antigen processing and presentation, enabling CD8+ T-cell-mediated immune surveillance against viral infections and malignant cells.
In pathological contexts, PSMB9 is implicated in autoimmune diseases, chronic inflammation, and various cancers. Overexpression of PSMB9 is observed in inflammatory conditions like rheumatoid arthritis and lupus nephritis, where it drives aberrant immune activation and cytokine production. Conversely, in oncology, PSMB9 expression is associated with tumor-immune infiltration and serves as a prognostic biomarker for response to immune checkpoint inhibitors and CAR-T cell therapies. Therapeutic targeting of PSMB9 involves both pan-proteasome inhibitors (such as bortezomib and carfilzomib) and selective immunoproteasome inhibitors (such as zetomipzomib/KZR-616 and experimental agents like KZR-504 or ML604440). Inhibiting PSMB9 disrupts immunoproteasome function, dampening autoimmune responses and inflammatory cytokine release, making it a highly promising target for autoimmune and inflammatory disorders.
Inhibition of the threonine-type endopeptidase activity of the immunoproteasome, preventing the degradation of intracellular proteins into peptides for MHC class I antigen presentation, thereby modulating immune responses and cytokine production.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteasome subunit beta type-9 (PSMB9).